Molecular therapy. Oncology · 2025
Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caputo Carlo, Donadelli Massimo, Scupoli Mariateresa, D'Arena Giovanni, Pietrantuono Giuseppe, Giudice Aldo, Giliberti Angela, Volpe Silvestro, Sperlongano Rossella, Cautela Domenico, Scafuri Bernardina, Facchiano Angelo, Cossu Alessia Maria, Bocchetti Marco, Misso Gabriella, Lombardi Angela, Caraglia Michele, Grimaldi Anna
Аннотация
Chronic lymphocytic leukemia (CLL) is characterized by a remarkably complex landscape. We performed a molecular characterization of liquid biopsies from 137 leukemia samples and 10 healthy subjects. Almost all patients express single-nucleotide polymorphism (SNP) mutations of the TP53 gene and the most common (n = 132 patients) was the Pro72Arg missense mutation. It was associated with significantly higher overall survival (p < 0.001) in untreated patients (n = 73) compared to treated patients (n = 58). However, this TP53 mutation is identified in both patients and healthy volunteers being likely a germinal mutation classified as SNP. In addition, a rare missense SNP mutation (Arg337Cys) of TP53 gene, correlated positively with clinical outcome (204 months; p = 0.00001) was also found. Its effects on p53 stability and function were subsequently evaluated. A missense mutation (Met541Leu) in the KIT gene was found in 18 patients and it was also significantly associated (p < 0.05) with a favorable outcome in untreated patients (n = 10) compared to treated ones (n = 8). We performed a comparative analysis among CLL patients classified into three prognostic groups (Binet A, B, and C). Survival analysis confirmed that Binet C patients had a significantly reduced survival compared to Binet A patients (p < 0.05).